Ads
related to: denosumab cancer- FAQs
Find FAQs for This
Treatment On The Official Site.
- Clinical Trial
Find Info on the Clinical Trial
For this Treatment Option.
- Caregiver Support
Find Resources for Caregivers
at the Official Site Today.
- Dosing Information
Learn About Dosing Schedules
For this Treatment Option.
- FAQs
Search results
Results From The WOW.Com Content Network
Denosumab is a human monoclonal IgG2 antibody that targets the protein RANKL, which is essential for the formation, function and survival of osteoclasts, the cell type responsible for bone resorption. [14] Denosumab binds to RANKL with high affinity and specificity, preventing the interaction between RANKL and RANK. [14]
The Food and Drug Administration has approved Amgen's (AMGN) osteoporosis drug denosumab for use by cancer patients with solid tumors whose disease has metastasized to their bones. The indication ...
About two out of every three breast cancer patients are hormone receptor positive. [25] In the past several years, denosumab has been used in clinical trials, primarily because a large population is affected by bone complication among those who have breast cancer. 252 patients enlisted in the HALT-BC clinical trial (also known as NCT00089661).
Breast cancer, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell head and neck cancer and gastric cancer. ... Denosumab: SC: RANKL inhibitor.
Prolia (denosumab) is an injectable medication that helps treat osteoporosis. ... males who have undergone treatment for prostate cancer and experienced bone loss.
ovarian cancer, malignant ascites, gastric cancer cBR96-doxorubicin immunoconjugate: mab: humanized: Lewis-Y antigen: cancer Cedelizumab [47] mab: humanized: CD4: prevention of organ transplant rejections, treatment of autoimmune diseases Cemiplimab [32] Libtayo: mab: human: PD-1: Y: cutaneous squamous cell carcinoma Cergutuzumab amunaleukin ...
Ads
related to: denosumab cancer